Point72 Middle East FZE’s HilleVax HLVX Stock Holding History

Point72 Middle East FZE’s Portfolio HLVX Stock Details HLVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-122	Closed	-$2.02K	–	1768
2023 Q1	$2.02K	Buy	+122	New	+$1.95K	﹤0.01%	1544

Other funds holding HLVX

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Point72 Middle East FZE's HLVX Position: Q2 2023 in Review

Point72 Middle East FZE sold out of HilleVax (HLVX) in Q2 2023, closing a stake of 122 shares — an estimated $2.02K sold.

Point72 Middle East FZE first reported a position in HLVX in Q1 2023 and held it in 1 quarter. The position peaked at $2.02K in Q1 2023. 54 funds tracked by Wall St. Rank hold HLVX as of Q2 2023.

Point72 Middle East FZE reported no remaining HilleVax position as of Q2 2023 after selling out during the quarter.
Point72 Middle East FZE sold 122 HilleVax shares in Q2 2023, an estimated $2.02K.
Point72 Middle East FZE first reported a position in HilleVax in Q1 2023 and held it in 1 quarter.
Point72 Middle East FZE's HilleVax position peaked at $2.02K in Q1 2023.
54 funds tracked by Wall St. Rank held HilleVax as of Q2 2023.

Based on Point72 Middle East FZE's 13F filing for Q2 2023, filed 14 Aug 2023.